Back to 
Farallon Capital Management, L.L.C.
Farallon Capital Management, L.L.C.
CRSP
Showing 1 of 10 quarters
Position history for Farallon Capital Management, L.L.C.'s holdings in CRISPR Therapeutics AG
No. Farallon Capital Management exited its CRSP (CRISPR Therapeutics) position in Q3 2024. Its Q2 2024 13F listed 530,000 shares worth $28.6M. Farallon Capital Management already held CRSP in its Q4 2018 13F, the earliest on record, and held it in 8 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
$0
Total Shares Change
0
Quarter-by-Quarter History